Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]
Discontinued
Reference number: GID-TA10164
The Department of Health has asked the Institute to conduct an appraisal of nivolumab for previously treated advanced hepatocellular carcinoma.
We have now been informed by the company that it will no longer be pursuing a licensing application, therefore, NICE has decided to suspend this appraisal from its current work programme. For more detailed information please refer to the EMA website.
The discussion of this appraisal planned for Thursday 12 October 2017 has been cancelled.
As this topic has been referred to the Institute we will continue to monitor any development and will update interested parties if the situation changes.